Not Signed In - Publications Feature VELCADE(R) (Bortezomib) For Injection Strength In Hematological Cancers
Tue, 05 Dec 2006 08:00 AM EST
... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the publication of clinical data of VELCADE in the treatment of newly diagnosed multiple myeloma (MM), MM accompanied by advanced renal failure, and mantle cell lymphoma (MCL). These data underscore the substantial activity and well-characterized safety profile of VELCADE in the treatment of hematological cancers. [click link for full article] ...
Related Topics
- Bortezomib
- Aluminum Hydroxide, Magnesium Carbonate Oral Suspension
- Dicyclomine Injection
- Acetaminophen and Aspirin and Caffeine powder
- Cortisone Injection
- Aluminum and Magnesium Hydroxide
- Other cancers
- Unusual Childhood Cancers
- Unusual Cancers of Childhood
- Bismuth Subsalicylate
- Pseudoephedrine and Dextromethorphan
- Cancers of the larynx, esophagus, liver, and colon
- Dimenhydrinate Injection
- Calcitonin Salmon Injection
- Sulfamethoxazole and Trimethoprim Injection
- Strength Sports
- Ibuprofen
- Strength & Weight Training
- Skin damage due to skin cancers
- Dexamethasone Injection
email this page
print this page
bookmark this page
feedback on this page
